Eli Lilly wraps up fifth and final tirzepatide PhIII trial, claiming a win over Sanofi's Lantus. The FDA awaits

Eli Lilly has long been testing its experimental tirzepatide candidate in diabetes, looking to see whether or not it can take over Trulicity’s diabetes mantle once the patent runs out in 2027. And on Thursday, the Big Pharma wrapped up its last registrational trial.